Malignant tumors can evade destruction by the immune system by attracting immune-
suppressive regulatory T cells (Treg) cells. The IKZF2 (Helios) transcription factor plays a …

The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all
approved for the treatment of multiple myeloma, induce targeted ubiquitination and …

Most intracellular proteins lack hydrophobic pockets suitable for altering their function with
drug-like small molecules. Recent studies indicate that some undruggable proteins can be …

IL-2 is a cytokine clinically approved for the treatment of melanoma and renal cell
carcinoma. Unfortunately, its clinical utility is hindered by serious side effects driven by the …

Immunomodulatory drugs are a class of drugs approved for the treatment of multiple
myeloma. These compounds exert their clinical effects by inducing interactions between the …

INTRODUCTION Thalidomide, lenalidomide, and pomalidomide are clinically approved
therapies for the treatment of multiple myeloma and other hematologic malignancies. These …

Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that degrade target
proteins through recruiting E3 ligases. However, their application is limited in part because …

Purpose: Aldesleukin, recombinant human IL2, is an effective immunotherapy for metastatic
melanoma and renal cancer, with durable responses in approximately 10% of patients; …

Immunomodulatory drugs (IMiDs) exert anti-myeloma activity by binding to the protein
cereblon (CRBN) and subsequently degrading IKZF1/3. Recently, their ability to recruit E3 …

PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested
extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also …